ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Methotrexate

Also written as “methotrexate”, “Methotrexate (MTX)” and “MTX”.

Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Gout · Arthritis, Psoriatic · Arthritis, Juvenile, led by 24 companies.

Drug pageMethotrexate: every studyMany companies study it; this page follows only the 93 they lead. All 627 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 18, 200793 company-led studies, 4 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only360 open or runningphase 4since Apr 18, 2007Oct 21, 2005none ahead
Bristol-Myers Squibb91 open or runningphase 4since Sep 4, 2015Jul 19, 2005none ahead
Pfizerits history only80 open or runningphase 4since Sep 8, 2005Sep 8, 2005none ahead
AbbVieits history only60 open or runningphase 4since May 25, 2010Sep 13, 2005none ahead
Johnson & Johnsonits history only60 open or runningphase 3since Dec 11, 2005Dec 11, 2005none ahead
Aldeyra Therapeuticsits history only31 open or runningphase 3since Oct 21, 2019Oct 21, 2019Dec 2029phase 3 · NCT07402876
AstraZenecaits history only30 open or runningphase 4since Aug 23, 2023Sep 16, 2005none ahead
medacits history only31 open or runningphase 3since Jan 11, 2024May 14, 2013Nov 2026phase 3 · NCT06239311
Merckits history only30 open or runningphase 3since Aug 18, 2006Aug 18, 2006none ahead
Halozyme Therapeuticsits history only20 open or runningphase 2since Jun 4, 2012Jun 4, 2012none ahead

Also a collaborator on its studies: Lakefront Biotherapeutics NV, Roche Pharma, Regeneron Pharmaceuticals, Integrated Therapeutics Group, Accutest Research Laboratories (I) Pvt., PPD DEVELOPMENT, LP, UCB, Immunex, Basilea Pharmaceutica International, Tanabe Pharma, Astellas Pharma US and Eisai.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 19, 2005First study: phase 3 study in Arthritis, RheumatoidFirst studyNCT00122382 · 1,052 enrolled · United States, Australia, Belgium and more
  2. Oct 6, 2008Phase 3 study in Arthritis, RheumatoidNCT00767325 · 104 enrolled · Denmark, France, Germany and more
  3. Jun 3, 2010Phase 3 study in Arthritis, RheumatoidNCT01142726 · 511 enrolled · United States, Australia, Belgium and more
  4. Jul 20, 2015Phase 3 study in Arthritis, RheumatoidNCT02504268 · 994 enrolled · United States, Argentina, Australia and more
  5. Sep 4, 2015Phase 4 study in Arthritis, RheumatoidNCT02557100 · 80 enrolled · United States, Canada, Mexico
  6. Feb 11, 2020Phase 1 study in Healthy VolunteerNCT04268394 · 48 enrolled · United Kingdom
  7. May 28, 2021Phase 3 study in Arthritis, RheumatoidNCT04909801 · 338 enrolled · United States, Argentina, Australia and more
  8. Jun 30, 2022Phase 1 study in Healthy ParticipantsNCT05445440 · 30 enrolled · United States
  9. Nov 7, 2022Phase 1 study in Healthy ParticipantsNCT05615012 · 76 enrolled · United States

TargetBeta

DHFR →read by rule
“Dihydrofolate reductase inhibitor; Dihydrofolate reductase inhibitor”ChEMBL 37, by rule

Other programs on DHFR

ProgramCompanyFurthest phaseStudies
PemetrexedruleEli Lillyphase 4141
pralatrexateruleAurobindo Pharmaphase 419

Studies

All 9 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05615012Healthy Participants · United States1CompletedDec 13, 202376
NCT05445440Healthy Participants · United States1CompletedNov 17, 202230
NCT04909801Arthritis, Rheumatoid · United States, Argentina, Australia and more3Active, not recruitingJun 14, 2023338
NCT04268394Healthy Volunteer · United Kingdom1CompletedJun 2, 202148
NCT02557100Arthritis, Rheumatoid · United States, Canada, Mexico4CompletedMar 28, 201980
NCT02504268Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedJan 16, 2017994
NCT01142726Arthritis, Rheumatoid · United States, Australia, Belgium and more3CompletedSep 2013511
NCT00767325Arthritis, Rheumatoid · Denmark, France, Germany and more3CompletedOct 2011104
NCT00122382Arthritis, Rheumatoid · United States, Australia, Belgium and more3CompletedFeb 20081,052

How it is read

Names in the registry

  • “Methotrexate”, 71 entries
  • “methotrexate”, 28 entries
  • “Methotrexate (MTX)”, 7 entries
  • “MTX”, 4 entries
  • “methotrexate (MTX)”, 3 entries

Codes read as this program: ADX2191.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.